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Aims In patients with sick sinus syndrome, bradycardia can be treated with a single-lead pacemaker or a dual-chamber
pacemaker. Previous trials have revealed that pacing modes preserving atrio-ventricular synchrony are superior to
single-lead ventricular pacing, but it remains unclear if there is any difference between single-lead atrial pacing
(AAIR) and dual-chamber pacing (DDDR).
Methods
and results
We randomly assigned 1415 patients referred for first pacemaker implantation to AAIR (n ¼ 707) or DDDR
(n ¼ 708) pacing and followed them for a mean of 5.4+ 2.6 years. The primary outcome was death from any
cause. Secondary outcomes included paroxysmal and chronic atrial fibrillation, stroke, heart failure, and need for
pacemaker reoperation. In the AAIR group, 209 patients (29.6%) died during follow-up vs. 193 patients (27.3%) in
the DDDR group, hazard ratio (HR) 1.06, 95% confidence interval (CI) 0.88–1.29, P ¼ 0.53. Paroxysmal atrial fibrilla-
tion was observed in 201 patients (28.4%) in the AAIR group vs. 163 patients (23.0%) in the DDDR group, HR 1.27,
95% CI 1.03–1.56, P ¼ 0.024. A total of 240 patients underwent one or more pacemaker reoperations during follow-
up, 156 (22.1%) in the AAIR group vs. 84 (11.9%) in the DDDR group (HR 1.99, 95% CI 1.53–2.59, P, 0.001).
The incidence of chronic atrial fibrillation, stroke, and heart failure did not differ between treatment groups.
Conclusion In patients with sick sinus syndrome, there is no statistically significant difference in death from any cause between
AAIR pacing and DDDR pacing. AAIR pacing is associated with a higher incidence of paroxysmal atrial fibrillation and
a two-fold increased risk of pacemaker reoperation. These findings support the routine use of DDDR pacing in these
patients. Clinical Trial Registration: URL http://www.clinicaltrials.gov. Unique identifier: NCT00236158.
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Introduction
In patients with sick sinus syndrome, bradycardia should be
treated with either a single-lead atrial pacemaker (AAIR) or
a dual-chamber pacemaker (DDDR). AAIR pacing necessitates
conduction over the atrio-ventricular node, which preserves the
normal ventricular contraction pattern, but it does not protect
against bradycardia if atrio-ventricular block subsequently
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develops. In contrast, DDDR pacing protects against bradycardia in
case of atrio-ventricular block, but it usually causes some degree of
unnecessary pacing in the right ventricle, which changes the elec-
trical activation and contraction pattern of the ventricles. This
may result in ventricular remodelling, with decreased left ventricu-
lar ejection fraction and left atrial dilatation,1– 3 which has been
associated with an increased risk of atrial fibrillation and heart
failure.4 –7 Therefore, we hypothesized that AAIR pacing was
superior to DDDR pacing in patients with sick sinus syndrome,
and we aimed to test that in a large-scale randomized trial.
Methods
Study design
We randomly assigned patients with sick sinus syndrome to AAIR
pacing or DDDR pacing. From 10 March 1999 to 30 June 2008, we
enrolled patients from all Danish pacemaker centres and from selected
centres in UK and Canada, and followed them until 15 September
2009. The trial was initiated by investigators from all Danish pacemaker
centres, and the trial design and the pacemaker programming were
agreed on after advice from an international Advisory Board (Appen-
dix). The trial was conducted in accordance with the Helsinki
Declaration and approved by the regional Ethics Committee and the
Danish Data Protection Agency. All patients gave their written
informed consent before inclusion.
Criteria for eligibility
All patients referred for first pacemaker implantation were evaluated
for inclusion. The criteria for inclusion were: symptomatic bradycardia;
documented sino-atrial block or sinus-arrest with pauses .2 s or sinus
bradycardia ,40 bpm for more than 1 min while awake; PR interval
≤0.22 s if aged 18–70 years or PR interval ≤0.26 s if aged ≥70
years; and QRS width ,0.12 s. The main exclusion criteria were: atrio-
ventricular block; bundle branch block; long-standing persistent atrial
fibrillation (.12 months); atrial fibrillation with ventricular rate
,40 bpm for ≥1 min or pauses .3 s; a positive test for carotid
sinus hypersensitivity; planned cardiac surgery; or a life-expectancy
shorter than 1 year (Figure 1). Documented paroxysmal atrial fibrilla-
tion was not an exclusion criterion. Randomization by sealed envelope
was performed before pacemaker implantation.
Implantation and programming
of pacemakers
A bipolar lead was implanted in the right atrium, and in patients
randomized to DDDR pacing an additional lead was implanted in the
Figure 1 Flow diagram: screening, exclusion, randomization, and follow-up of patients. At last follow-up, four patients in the AAIR group and
two patients in the DDDR group had a DDDR pacemaker programmed with features automatically prolonging or eliminating the atrioventri-
cular interval to withhold ventricular pacing.
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right ventricle. An atrial pacing test was performed at 100 bpm in all
patients and 1:1 atrio-ventricular conduction was required for implan-
tation of an AAIR pacemaker. In patients randomized to AAIR pacing
demonstrating atrio-ventricular block when paced at 100 bpm, a ven-
tricular lead and a DDDR pacemaker were implanted. Patients with
atrial fibrillation during implantation either underwent DC cardiover-
sion or received a pacemaker system without an atrial pacing test at
the implanter’s discretion.
The rate adaptive function was activated in all pacemakers and
programmed with a lower rate of 60 bpm and an upper rate of
130 bpm. In patients with DDDR pacemakers, the paced atrio-
ventricular interval was programmed to 140–220 ms according to
a pre-specified algorithm: the paced atrio-ventricular interval was
initially programmed to a value 10% longer than either the interval
measured from the atrial pacing spike to start of the conducted
QRS complex at 60 bpm or the PR interval if the sinus rate was
faster than 60 bpm. If ventricular pacing occurred with this program-
ming, the paced atrio-ventricular interval was gradually increased in
steps of 20 ms until ventricular pacing ceased or until a maximum of
220 ms was reached. If ventricular pacing still occurred at a pro-
grammed interval of 220 ms, the paced atrio-ventricular interval
was shortened to a length of 140–160 ms, and the atrio-ventricular
hysteresis function was activated to allow automatic search for
intrinsic atrio-ventricular conduction with an atrio-ventricular inter-
val of 220 ms. The atrio-ventricular interval after sensed atrial
beats was set 20–30 ms shorter than the paced interval, and auto-
matic shortening of the atrio-ventricular interval was allowed during
rate increases. The maximum tracking rate was individualized and
the mode switch function was activated.
Patient follow-up
Follow-up took place after 3 months and again every year after implan-
tation up to 10 years. At each planned follow-up visit, a printout was
made of the pacemaker memory data accumulated since the previous
resetting of the memory. The percentage of atrial and ventricular
pacing at each follow-up was calculated using the number of paced
and the number of sensed beats. The mean pacing percentage through-
out the total follow-up period was computed for each patient by cal-
culating the mean of these values. A 12-lead ECG was recorded and
the atrial electrogram was obtained from the pacemaker telemetry
to document the atrial rhythm. Furthermore, information regarding
secondary outcomes and medication was collected. At the end of
each planned follow-up visit, the correct programming of the
atrio-ventricular delay was ensured according to the pre-specified
algorithm, and the pacemaker memory was reset. Once every
month, new deaths were identified by checking the study database
against the Danish Civil Registration System and supplementary infor-
mation regarding deceased patients was collected from hospitals and
general practitioners.
Study outcomes
The primary outcome was death from any cause. Secondary out-
comes included paroxysmal atrial fibrillation; chronic atrial fibrilla-
tion; stroke; peripheral embolism; heart failure; and need for
pacemaker re-operation. Paroxysmal atrial fibrillation was defined
as the first diagnosis of atrial fibrillation at a planned follow-up
visit and chronic atrial fibrillation was defined as atrial fibrillation
at two consecutive follow-up visits and at all subsequent follow-up
visit. First cardioversion for atrial fibrillation after hospital discharge
was recorded. Stroke was defined as: the sudden development of
focal neurological symptoms lasting more than 24 h. A diagnosis
of peripheral embolism required confirmation at autopsy,
intra-operatively (during embolectomy), or at angiography.
New York Heart Association (NYHA) functional class, use of diure-
tics, and hospitalization for heart failure were used as indicators of
heart failure. Need for pacemaker reoperation was decided by the
physician in charge of follow-up. The investigators were asked to
only change the pacing mode from AAIR to DDDR pacing in
cases of high-grade atrio-ventricular block or documented sympto-
matic atrio-ventricular block of the Wenckebach type. The
incidental finding of a low Wenckebach block point at a follow-up
visit was not an indication for change of pacing mode. A Clinical
Event Committee (Appendix), which was unaware of the assigned
pacing mode adjudicated stroke and thrombo-embolic events.
Statistical plan and analysis
In an earlier trial comparing AAIR pacing and single-lead ventricular
pacing in patients with sick sinus syndrome, mortality was signifi-
cantly higher in the single-lead ventricular group.5 We assumed
that the relative difference in mortality between AAIR pacing and
DDDR pacing would be half the difference observed between
AAIR pacing and single-lead ventricular pacing. Therefore, the
study was planned to include 1900 patients followed for a mean
of 5.5 years to identify a 6% absolute difference (32 vs. 26%) in
death from any cause between treatment groups, with a power of
80% and an overall a ¼ 0.05. An independent Safety and Ethical
Committee (Appendix) monitored two planned interim analyses
performed after one-third and two-thirds of the expected number
of deaths. The first interim analysis was planned with a conservative
a ¼ 0.001, and subsequently with a ¼ 0.016 and a ¼ 0.044 at the
second interim and final analysis, respectively. According to the
study plan, the trial would only be stopped early in case of a signifi-
cant result at an interim analysis. An unplanned interim analysis with
respect to the occurrence of atrial fibrillation was performed at the
request of the Safety and Ethical Committee after publication of the
Search AV Extension and Managed Ventricular Pacing for Promoting
Atrioventricular Conduction (SAVE PACe) Trial in 2007.7 Due to
the increasing use of dual-chamber pacemakers with new features
prolonging or eliminating the atrio-ventricular interval in order to
minimize ventricular pacing in patients with sick sinus syndrome,
which were not permitted in the trial, the recruitment rate
decreased in several Danish centres from 2005. Therefore, collabor-
ation was established with pacemaker centres in Canada and the UK
with the expectation that 400 patients from these countries
would be enrolled during a 2-year period. Recruitment was com-
menced in the UK in May 2007 and in Canada in July 2007. By
June 2008, a total of 31 patients had been enrolled between the
two countries and it was clear that the planned enrolment of 400
patients could not be achieved. Consequently, it was decided to
stop enrolment on 30 June 2008. After advice from the Safety
and Ethical Committee, the investigators decided to stop follow-up
on 15 September 2009.
Fewer than the planned 1900 patients were included in the study.
From the second planned interim analysis, it could be foreseen that
no significant difference could be reached with respect to the
primary outcome even with the planned 1900 patients.
Treatment groups were compared on an intention-to-treat basis.
Statistical tests were two-tailed, and P, 0.05 was considered signifi-
cant. Mean+ SD are reported for continuous data. Cumulative
event rates were calculated by the Kaplan–Meier method and the
log-rank test was used for comparison between groups. Relative
risk was expressed as hazard ratio (HR) with 95% confidence inter-
val (CI). Pre-specified supplemental analyses adjusting for baseline
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characteristics were done using Cox proportional-hazards regression
analysis. Categorical variables were compared by means of the Pear-
son’s chi-square test and continuous variables by means of the
Mann–Whitney test. Post-hoc, a supplementary on-treatment analy-
sis was done comparing the outcomes ‘death from any cause’ and
‘paroxysmal atrial fibrillation’ between patients randomized to and
treated with single-lead atrial pacemakers and dual-chamber pace-
makers, respectively, during the whole study period.
The interim analysis design was a hybrid of a Pocock design and an
O’Brien-Fleming design, and was performed using the EaSt software
package, version 2.0 (Cytel Software). Data management was done
using SIR/DBMS and SIR/FORMS (SIR Database Software), and
statistical analysis was performed using SPSS/PASW version 18,
BMDP release 8.1, and STATA version 11.
Results
Study population
After screening 18 553 patients referred for first pacemaker
implantation, a total of 1415 patients were included and underwent
pacemaker implantation (Table 1). At implantation, 93.4% of the
patients randomized to AAIR pacing and 98.9% of the patients ran-
domized to DDDR pacing were implanted as assigned (Figure 1).
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Table 1 Baseline characteristics of the patients
Characteristic AAIR (n5 707) DDDR (n 5 708) P-value
Female gender, n (%) 472 (66.8) 441 (62.3) 0.08
Age, years (mean+ SD) 73.5+11.2 72.4+11.4 0.054
Body mass index (mean+ SD) 26 (4) 26 (4) 0.62
Prior history of atrial fibrillation, n (%) 303 (42.9) 318 (44.9) 0.44
Hypertension, n (%) 241 (34.1) 239 (33.8) 0.90
Previous myocardial infarction, n (%) 94 (13.3) 90(12.7) 0.74
Diabetes, n (%) 68 (9.6) 72 (10.2) 0.73
Previous transient cerebral ischaemia, n (%) 35 (5.0) 37 (5.2) 0.81
Previous stroke, n (%) 61 (8.6) 53 (7.5) 0.43
Left ventricular ejection fraction reduced (, 50%), n (%) 59 (10.6) 54 (9.5) 0.55
Left ventricular end-diastolic diameter in mm, mean+ SD 47.7+7.3 47.8+7.3 0.45
Left atrial diameter in mm, mean+ SD 39.3+6.5 38.8+6.4 0.23
Symptoms before pacemaker, n (%)
Syncope 359 (50.8) 349 (49.3) 0.58
Dizzy spells 597 (84.4) 587 (82.9) 0.44
Heart failure 86 (12.2) 79 (11.2) 0.56
≥2 of the above three symptoms 317 (44.8) 291 (41.1) 0.16
Medication at randomization, n (%)
Anticoagulation 108 (15.3) 89 (12.6) 0.14
Aspirin 369 (52.2) 361 (51.1) 0.67
Sotalol 43 (6.1) 44 (6.2) 0.91
Beta-blocker other than sotalol 159 (22.5) 132 (18.7) 0.08
Calcium-channel blocker 137 (19.4) 142 (20.1) 0.75
Digoxin 73 (10.3) 62 (8.8) 0.32
Amiodarone 25 (3.5) 24 (3.4) 0.88
Class I antiarrhythmics 14 (2.0) 20 (2.8) 0.30
Angiotensin-converting-enzyme inhibitors 160 (22.6) 170 (24.0) 0.53
Diuretics 304 (43.0) 263 (37.2) 0.03
NYHA class, n (%) 0.33
I 503 (71.4) 522 (73.9)
II 172 (24.4) 158 (22.4)
III 29 (4.1) 24 (3.4)
IV 0 2 (0.3)
Wenckebach block point ≥100 bpm (%) 611 (94.1) 581 (91.6) 0.08
Treated as randomized 660 (93.4) 700 (98.9) ,0.001
The data were not complete for the following parameters: body mass index (AAIR: n ¼ 646, DDDR: n ¼ 637), left ventricular ejection fraction (AAIR: n ¼ 558, DDDR: n ¼ 569),
left ventricular end-diastolic diameter (AAIR: n ¼ 479, DDDR: n ¼ 507), left atrial diameter (AAIR: n ¼ 506, DDDR: n ¼ 517), medications except calcium channel blocker (AAIR:
n ¼ 707, DDDR: n ¼ 707), NYHA class (AAIR: n ¼ 704, DDDR: n ¼ 706), and Wenckebach block point ≥100 bpm (AAIR: n ¼ 649, DDDR: n ¼ 634).
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The mean duration of follow-up until death or end of study was
5.4+ 2.6 years. The mean percentage of atrial pacing was 58+
29% in the AAIR group and 59+ 31% in the DDDR group (P ¼
0.52). The mean percentage of ventricular pacing was 65+33%
in the DDDR group. In the AAIR group, 585 patients (83%)
never had a ventricular lead. In the remaining 122 patients, a ven-
tricular lead was implanted at the first operation or at some point
during follow-up. Pacemaker memory data were recorded in 103
of these 122 patients, and showed a mean of 53+35% of ventri-
cular pacing. At the end of follow-up, the mean programmed
maximum paced atrio-ventricular delay in the dual-chamber
group was 225+39 ms.
Death from any cause
In the AAIR group, 209 patients (29.6%) died during follow-up vs.
193 patients (27.3%) in the DDDR group, HR 1.06; 95% CI 0.88–
1.29, P ¼ 0.53. Kaplan–Meier plots are shown in Figure 2. Patients
randomized to DDDR pacing were slightly younger and, after cor-
recting for differences in baseline variables, the adjusted mortality
HR was 0.94, 95% CI 0.77–1.14, P ¼ 0.52 for AAIR pacing vs.
DDDR pacing (Table 2). The incidence of death from any cause
was similar in all predefined subgroups (Figure 3). Variables signifi-
cantly associated with death from any cause in multivariate analysis,
including treatment group, were age (HR per year 1.093, 95% CI
1.079–1.107, P, 0.001), left ventricular ejection fraction below
50% (HR 1.82, 95% CI 1.33–2.48, P, 0.001), and prior myocardial
infarction (HR 1.51, 95% CI 1.15–1.98, P ¼ 0.003).
Atrial fibrillation
Paroxysmal atrial fibrillation was observed more frequently in the
AAIR group than in the DDDR group, HR 1.27, 95% CI 1.03–
1.56, P ¼ 0.024, also after correction for baseline variables
(Table 2, Figure 2). The incidence of chronic atrial fibrillation did
not differ between the groups (HR 1.02, 95% CI 0.74–1.39, P ¼
0.93) (Table 2). The strongest predictor of paroxysmal atrial fibril-
lation was prior history of atrial fibrillation (HR 3.23, 95% CI 2.59–
4.03, P, 0.001). First cardioversion for atrial fibrillation was done
in 32 patients in the AAIR group vs. 20 patients in the DDDR
group (HR 1.60, 95% CI 0.92–2.80, P ¼ 0.10).
In the subgroup analysis, three significant interactions and one
borderline significant interaction were observed: the incidence of
paroxysmal atrial fibrillation was less with DDDR pacing in the
Figure 2 Time-to-event curves for the primary outcome and selected secondary outcomes. Atrial fibrillation denotes paroxysmal atrial fibril-
lation defined as: the first diagnosis of atrial fibrillation at a planned follow-up visit. Unadjusted P-values (log-rank test) are shown.
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subgroups of patients without a prior history of atrial fibrillation,
with a longer PQ interval, a higher body-mass index, and a
dilated left atrium at baseline (Figure 4). P-values for all interactions
were ,0.05 except for PQ interval with P ¼ 0.084.
Stroke and peripheral embolism
Stroke was diagnosed in 39 patients (5.5%) in the AAIR group and
34 patients (4.8%) in the DDDR group (HR for AAIR group 1.13,
95% CI 0.72–1.80, P ¼ 0.59) (Figure 2, Table 2). The only predic-
tors of stroke in a multivariate analysis were age (HR per year
1.037, 95% CI 1.012–1.062, P ¼ 0.004) and gender (HR for
women 0.56, 95% CI 0.35–0.91, P ¼ 0.02). Peripheral embolism
was diagnosed in one patient in the AAIR group and in two
patients in the DDDR group.
Heart failure
NYHA class did not differ between groups at inclusion (Table 1) or
at last follow-up, where the number of patients in class I/II/III/IV
were 341/260/61/4 in the AAIR group vs. 364/231/67/4 in the
DDDR group, P ¼ 0.43. The proportion of patients treated with
diuretics at last follow-up was 324/692 (46.8%) in the AAIR
group vs. 328/695 (47.2%) in the DDDR group, P ¼ 0.89. Hospital-
ization for heart failure occurred in 27 patients in the AAIR group
vs. 28 patients in the DDDR group (P ¼ 0.90).
Pacemaker reoperations
A total of 240 patients underwent one or more pacemaker reo-
perations during follow-up, 156 (22.1%) in the AAIR group vs.
84 (11.9%) in the DDDR group (HR 1.99, 95% CI 1.53–2.59,
P, 0.001) (Table 3).
Drug treatment during follow-up
Comparing drug treatment at last follow-up between the two
groups revealed no significant differences: beta-blocker: 281/692
(41%) in the AAIR group vs. 274/695 (39%) in the DDDR group,
P ¼ 0.65; sotalol: 27/692 (4%) vs. 28/695 (4%), P ¼ 0.90; calcium-
channel blocker: 162/692 (23%) vs. 174/695 (25%), P ¼ 0.48;
amiodarone: 37/692 (5%) vs. 37/695 (5%), P ¼ 0.99; class I
antiarrhythmics: 13/692 (2%) vs. 11/694 (2%), P ¼ 0.68; and antic-
oagulation: 170/692 (25%) vs. 175/695 (25%), P ¼ 0.72.
On-treatment analysis
A total of 584 patients in the AAIR group and 639 patients in the
DDDR group were treated as randomized throughout the entire
study period. Comparing these two groups, we found no differ-
ence in death from all causes (HR for AAIR pacing 1.01, 95% CI
0.82–1.24, P ¼ 0.93), whereas the difference in atrial fibrillation
was more marked than in the intention-to-treat analysis (HR for
AAIR pacing 1.42, 95% CI 1.12–1.81, P ¼ 0.0038), also after adjust-
ing for age, gender, and prior history of atrial fibrillation (HR 1.36,
95% CI 1.07–1.73, P ¼ 0.012).
Discussion
The present trial is the first large multicentre trial to compare
AAIR pacing with DDDR pacing in patients with sick sinus syn-
drome. The primary result was that no statistically significant differ-
ence was observed in survival between AAIR pacing and DDDR
pacing. AAIR pacing was associated with a higher incidence of par-
oxysmal atrial fibrillation, and a two-fold increase in the risk of
pacemaker reoperation during long-term follow-up. These findings
suggest that DDDR pacing programmed with a moderately pro-
longed atrio-ventricular interval may be a better choice of pacing
mode than AAIR pacing for patients with sick sinus syndrome.
More than a decade ago, a small randomized trial showed better
overall survival with AAIR pacing than with single-lead ventricular
pacing.5 Since the current trial was initiated, three large trials com-
paring single-lead ventricular and dual-chamber pacing in different
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Table 2 Clinical outcomes: unadjusted and adjusted hazard ratios
AAIR, n (%) DDDR, n (%) Unadjusted HR Unadjusted 95% CI P-value
Death from any cause 209 (29.6) 193 (27.3) 1.06 0.88–1.29 0.53
Paroxysmal atrial fibrillation 201 (28.4) 163 (23.0) 1.27 1.03–1.56 0.024
Chronic atrial fibrillation 79 (11.2) 76 (10.7) 1.02 0.74–1.39 0.93
Stroke 39 (5.5) 34 (4.8) 1.13 0.72–1.80 0.59
Pacemaker reoperation 156 (22.1) 84 (11.9) 1.99 1.53–2.59 ,0.001
Adjusted HR Adjusted 95% CI P-value
Death from any cause 0.94 0.77–1.14 0.52
Paroxysmal atrial fibrillation 1.24 1.01–1.52 0.042
Chronic atrial fibrillation 1.01 0.74–1.39 0.93
Stroke 1.11 0.70–1.77 0.65
Pacemaker reoperation 2.00 1.54–2.61 ,0.001
Death from any cause, paroxysmal atrial fibrillation, and chronic atrial fibrillation were adjusted for age, gender, prior history of atrial fibrillation, prior myocardial infarction, left
ventricular ejection fraction lower than 50%, and hypertension. Stroke was adjusted for age, gender, prior history of atrial fibrillation, hypertension, and prior stroke, whereas
pacemaker reoperation was adjusted for age, gender, prior history of atrial fibrillation, prior myocardial infarction, left ventricular ejection lower than 50%. Paroxysmal atrial
fibrillation was defined as the first diagnosis of atrial fibrillation at a planned follow-up visit.
CI, confidence interval.
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patient populations have been published.8 –10 In these trials, pacing
mode had no influence on overall mortality in patients with sinus
node disease or atrio-ventricular block.11 The current study is
the first large trial to demonstrate that the presence of a ventricu-
lar lead, with some degree of ventricular pacing in the DDDR
mode, as implemented in this trial, has no adverse effect on survival
in patients with sick sinus syndrome. These findings support the
contention that pacing mode has no significant influence on survi-
val in patients with sick sinus syndrome and preserved left ventri-
cular function.
Unexpectedly, we found a lower incidence of paroxysmal atrial
fibrillation in the DDDR group than in the AAIR group. Modern
DDDR pacemakers can report time in mode-switch as a very sen-
sitive measure of atrial fibrillation, but no comparable data are
available from AAIR pacemakers. Although the methods used in
this study were likely to underdiagnose paroxysmal atrial
fibrillation, they were systematic and the same in both treatment
arms and should therefore yield an unbiased estimate of the influ-
ence of pacing mode on the development of atrial fibrillation. Fur-
thermore, given the era in which this study was initiated (the
1990s) and the fact that pacemakers from every manufacturer
were allowed, we feel that the methods to detect atrial fibrillation
in our trial could not have been improved. Supporting the finding
of more atrial fibrillation in the AAIR group, we observed a trend
towards more patients undergoing their first cardioversion for
atrial fibrillation in the AAIR group.
How can a higher incidence of atrial fibrillation with AAIR pacing
be explained? The benefit of preserving atrio-ventricular synchrony
in avoiding atrial fibrillation is well established from large randomized
trials.8,9 In the current trial, the reason for excess atrial fibrillation in
the AAIR group may be the prolonged atrio-ventricular conduction
that is often observed with atrial pacing. Prolonged atrio-ventricular
Figure 3 Hazard ratios for death from any cause are shown for different subgroups. CI, confidence interval; LVEF, left ventricular ejection
fraction; MI, myocardial infarction; NYHA, New York Heart Association functional class. Smallest P-value for interaction was 0.45.
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conduction reduces ventricular preload and causes mitral regurgita-
tion.12 This accords with the finding that the benefit of DDDR pacing
on atrial fibrillation in the present trial was restricted to the subgroup
with longer PQ interval at baseline. It also accords with the results
found in a large community-based cohort study, where prolonged
atrio-ventricular conduction was associated with development of
atrial fibrillation.13 Furthermore, in patients with implantable defibril-
lators, prolonged PR interval was found to be associated with a worse
prognosis with atrial pacing.14 The programming of a lower rate of
60 bpm can be criticized, as atrio-ventricular conduction often pro-
longs during atrial pacing.15 However, this is the same lower rate as
was used in other large trials in sick sinus syndrome7,9 and the rate
was the same in the two groups, as was the frequency of atrial pacing.
In sick sinus syndrome, DDDR pacing with a very short
atrioventricular interval and more than 99% ventricular pacing has
been reported to increase the incidence of atrial fibrillation, when
compared with DDDR pacing with automated features to minimize
ventricular pacing by prolonging or eliminating the atrioventricular
interval.7 Post hoc analysis of data from the Mode Selection Trial in
Sinus-Node Dysfunction indicated an association between ventricu-
lar pacing and atrial fibrillation.6 In contrast to these findings, we
found less atrial fibrillation with DDDR pacing and a mean of
65% ventricular pacing when compared with AAIR pacing.
The most likely explanation of this disparity is the difference in
pacemaker programming. Our patients all had preserved atrio-
ventricular conduction at baseline. To promote intrinsic atrioventri-
cular conduction in the DDDR group, we programmed a moder-
ately prolonged atrio-ventricular interval, with a maximum of
220 ms. This probably resulted in less ventricular desynchroniza-
tion. The present findings suggest that DDDR pacing with a
Figure 4 Hazard ratios for paroxysmal atrial fibrillation are shown for different subgroups. CI, confidence interval; LVEF, left ventricular ejec-
tion fraction; MI, myocardial infarction; BMI, body mass index. P-values for interaction were ,0.05 for history of atrial fibrillation, BMI, and left
atrial diameter, P ¼ 0.084 for PQ interval, all other P-values for interaction were greater than 0.34.
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moderately prolonged atrio-ventricular interval may be a good
alternative to DDDR pacemakers with automated features to mini-
mize ventricular pacing for patients with sick sinus syndrome.
However, no direct comparison has been made between these
two pacing modes. The algorithms used to minimize ventricular
pacing can, in rare cases, cause inadvertent bradycardia16 and
pose a risk of potentially lethal bradycardia-related tachyarrhyth-
mias.17 –19
The subgroup analysis on paroxysmal atrial fibrillation indicated
that atrial fibrillation was significantly less frequent with DDDR
pacing in the group of patients without a history of atrial fibrillation
at time of pacemaker implantation, but not in the group who had a
prior history of atrial fibrillation. Similar results were reported
from the Mode Selection Trial in Sinus-Node Dysfunction, where
a significant reduction in atrial fibrillation with DDDR pacing
when compared with single-lead ventricular pacing was observed
solely in the subgroup of patients without a history of atrial fibrilla-
tion.9 These results support that pacing mode selection is less
important with respect to later development of atrial fibrillation
in patients who already have a history of prior atrial fibrillation,
and therefore are at the higher risk of later atrial fibrillation. In con-
trast, pacing mode selection seems to be more important for later
occurrence of atrial fibrillation in patients who never had atrial
fibrillation. However, these results were generated in subgroup
analysis, and therefore should be interpreted cautiously.
In patients with severely compromised left ventricular function,
ventricular pacing promotes heart failure, most likely due to ventri-
cular desynchronization.20 In patients with preserved left ventricu-
lar function, DDDR pacing with a short atrioventricular interval
and a high percentage of ventricular pacing also results in a
reduced left ventricular ejection fraction.2,21,22 Analysis of data
from the Mode Selection Trial in Sinus-Node Dysfunction
showed that patients without heart failure who had normal
ejection fraction and normal QRS duration at baseline tolerated
atrioventricular synchronous ventricular pacing for years.23 In
accordance with these findings, we found no difference in
hospitalizations for heart failure, New York Heart Association
functional class, or use of diuretics between treatment groups
after a mean of 5.4 years of follow-up.
The risk of undergoing pacemaker reoperation was twice as high
in the AAIR group when compared with the DDDR group. This
difference was mainly due to an increased need for a change of
pacing mode in the AAIR group, which occurred in 9.3% of the
patients, or a mean of 1.7% per year. The need to change the
pacing mode in 1.7% of patients per year in the AAIR group
strengthens the case for DDDR pacing as the preferred initial
pacing mode. Any pacemaker reoperation is associated with a
2% risk of device infection, with a potential need to extract the
complete pacemaker system.24,25 These findings suggest that
when a patient with an AAIR pacemaker is referred for a generator
replacement or other reoperation, consideration should be given
to implanting a DDDR pacing system to prevent future unplanned
reoperations for a system change.
Reoperation because of battery depletion also occurred slightly
more frequent in the AAIR group. This may reflect that many
DDDR pacemakers are larger with greater battery capacity than
smaller single chamber devices. However, the difference was not
statistically significant and the finding may be incidental.
Only 1415 of the planned 1900 patients were included in the
present trial, and this is a limitation that has to be taken into
account when interpreting the findings. Because of the growing
opinion in the pacing community that pacing the right ventricle
was harmful, it became increasingly difficult to include patients in
the trial as physicians chose to implant a DDDR pacemaker with
features prolonging or eliminating the atrioventricular interval
instead.26 Owing to the inclusion of fewer patients than initially
planned, the power of the study was attenuated and the possibility
of a small difference in all-cause mortality between DDDR pacing
and AAIR pacing cannot be ruled out with certainty. However, the
trial does include data from 1415 patients followed for a mean of
5.4 years, a total of more than 7600 years of follow-up, and no
patients were lost for follow-up. From the second planned
interim analysis, it could be foreseen that no significant difference
could be reached with respect to the primary outcome even with
enrolment of the planned 1900 patients.
Conclusion
In patients with sick sinus syndrome, there is no statistically signifi-
cant difference in death from any cause between AAIR pacing and
DDDR pacing programmed with a moderately prolonged atrioven-
tricular interval. AAIR pacing is associated with a higher incidence
of paroxysmal atrial fibrillation and a two-fold increased risk of
pacemaker reoperation. These findings support the routine use
of DDDR pacing in these patients.
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